Invus
Crossover fundNew York · Pre-Seed–Late Stage · 8 people tracked
Also known as INVUS FINANCIAL ADVISORS, LLC
Find your way into Invus
603 people in our graph share verified history with the Invus team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Invus combines the long time horizon and personal attention of a family office with the capabilities of a multi-strategy firm. Anchored by a continuous capital structure funded by Artal since 1985, it invests without predetermined exit timelines, allowing it to support companies from early stages through public-company status. The private equity team makes a handful of transformational investments each year as sole or lead partner, holding minority or majority stakes. The public equity team runs a concentrated long-only portfolio with multi-year holds. Invus Opportunities invests globally in private technology businesses across fintech, marketplaces, healthcare, AI/software, and other tech-enabled sectors. The firm emphasizes alignment, avoiding transaction and monitoring fees.
Source: firm website, verified Sep 1, 2026.
Team · 8 people
from the firm's website & public directories
What they invest in
from 22 of 23 portfolio companiesBiotech ×18Healthtech ×10AI & Machine Learning ×4Deep Tech ×4Medical Devices ×4Digital Health ×3Enterprise Software ×2Advanced Manufacturing ×1
HQs:United States×14France×1United Kingdom×1Japan×1Netherlands×1
Investments · 23 tracked
founders shown can be your intro pathBy year:2026 · 52025 · 22024 · 42023 · 22022 · 215 dated
Absci uses an AI-based drug creation platform combined with wet lab validation to design biologic therapeutics such as antibodies from scratch.
AI & Machine LearningBiotechDeep TechPortland, US
Sean McClain(Executive Officer)inPhil Barish(Executive Officer)in
BoardZach Jonasson(Director)Daniel Gold(Director)Bryan Lawlis(Director)
Co-investorsDas & Co.Oregon Venture FundPhoenix Venture PartnersTachyon VenturesTau VenturesBiotechnology Value Fund+2 more
Agenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL.
BiotechHealthtechLexington, US
Garo Armen(Chairman & CEO, Co-founder)Ozer Baysal(Executive Officer)Robert Stein(Executive Officer)Christine Klaskin(Executive Officer)inKaren Valentine(Executive Officer)Steven O'Day(Chief Medical Officer)in
Co-investorsAdvent Life SciencesGrazia Equity GmbHHEALTHCARE ROYALTY PARTNERSOberland CapitalCommodore CapitalLigand Pharmaceuticals+1 more
Cyclerion is a biopharmaceutical company developing therapeutics for neuropsychiatric diseases, with a lead candidate (CYC-126) for treatment-resistant depression that pairs anesthetic agents with a personalized biofeedback-driven device.
BiotechDigital HealthMental HealthCambridge, US
William Huyett(Executive Officer)Mark G. Currie(Executive Officer)inOle Isacson(Director)Stephanie Lovell(Director)Marsha Fanucci(Director)George Conrades(Director)
Co-investorsPappas CapitalPolaris Partners
Sereact builds AI foundation models that enable industrial robots to perform complex manipulation tasks like warehouse picking and returns handling without retraining.
Advanced ManufacturingAI & Machine LearningDeep TechEnterprise SoftwareQuantum ComputingRoboticsOxford, GB
Ralf Gulde(CEO and co-founder)Marc Tuscher(CTO and co-founder)Gerald Mullally(CEO)
Co-investorsAlpha EdisonBritish Business BankChevron Technology VenturesOxford Science EnterprisesBackstage AB
Leyden Labs develops nasal sprays containing antibodies that target respiratory viruses such as influenza and COVID at the nasal mucosa to prevent initial infection and transmission.
BiotechDeep TechHealthtechLeiden, NL
Koenraad Wiedhaup(Founder & Chief Executive Officer)inRonald Brus(Founder & Chief Growth Officer)inJaap Goudsmit(Founding Scientist and Senior Advisor)inDinko Valerio(Founder and Chair of the Supervisory Board)inJintanat Ananworanich(Chief Medical Officer)inClarissa Koch(Chief Scientific Officer)in
Co-investorsClavystBioF-Prime CapitalGV (Google Ventures)Bluebird VenturesCasdin CapitalEuropean Innovation Council Fund+5 more
Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform.
BiotechHealthtechSan Diego, US
Vijaya Pattabiraman(Co-founder & Chief Technology Officer)inJeffrey Bode(Scientific Co-founder)inFredrik Wiklund(Chief Executive Officer)Christine Siu(Director)Michael Rosenzweig(Director)Bertolt Kreft(Executive Officer)
Co-investorsRA CapitalJohnson & Johnson Innovation – JJDCVersant VenturesVenrockFidelity InvestmentsQatar Investment Authority
Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization.
BiotechDigital HealthHealthtechMedical DevicesBurlington, US
Michael E. Mendelsohn(Founder and Chief Strategy Officer)inMichael Mendelsohn, M.D.(Founder)in
Co-investorsBain CapitalDelos CapitalDigitalis VenturesNew Enterprise Associates (NEA)Ascenta CapitalBain Capital Life Sciences+4 more
City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.
BiotechMedical DevicesCambridge, US
Mark Keating, MD(Co-founder)Kotaro Nakanishi, PhD(Co-founder)Yukihide Tomari, PhD(Co-founder)Phillip Zamore, PhD(Co-founder)
Co-investorsAN Venture PartnersARCH Venture PartnersSofinnova VenturesCasdin CapitalFidelity InvestmentsRock Springs Capital
Coave Therapeutics develops targeted gene therapy vectors using its proprietary ALIGATER platform to deliver therapeutic genes to specific tissues with improved safety and precision.
BiotechDeep TechHealthtechMedical DevicesParis, FR
Co-investorsFund+Kurma PartnersSeroba Life SciencesV-Bio VenturesBpifranceNovo Holdings+1 more
BiotechCambridge, US
Philip Kantoff(Executive Officer, Director)inNeil Bander(Executive Officer, Director)Eric Sullivan(Executive Officer)inAlexander Brown(Executive Officer)in
BoardJake Simson(Director)inTal Zaks(Director)
Co-investorsOrbiMedRA Capital
Datawords operates a network of production studios across local markets to create and deliver localized content at scale for global brands.
AI & Machine LearningEnterprise SoftwareMarketing TechMedia & EntertainmentSector Agnostic
Co-investorsKeensight Capital
Flare develops AI-driven systems to manage essential workers—such as drivers, cleaners, security guards, and domestic workers—in emerging markets, vertically integrating its technology platform, worker staffing (via subsidiary Drive-Z), and customer implementation.
AI & Machine LearningFuture of WorkHR TechTokyo, JP
Kazuki Kamiya(CEO)Satoru Ichihara(COO)Shinya Hayashi(CSO)Hidefumi Iwaki(CFO)Tomohiro Sasaki(Executive Officer (Product Development))
Co-investorsANOBAKACARTA VENTURES, Inc.Spiral VenturesAgent CapitalCasdin CapitalNextech Invest+2 more
BiotechCambridge, US
Geoff McDonoughy(Executive Officer, Director)Glenn Goddard(Executive Officer)Mark Angelino(Executive Officer)
BoardJason Rhodes(Director)inCatherine Stehman-Breen(Director)Anthony Quinn(Director)
Co-investorsAtlas VentureForesite CapitalF-Prime Capital
Aesthetic-medicine biopharma behind KYBELLA (deoxycholic acid) injection, acquired by Allergan in 2015 for ~$2.1 billion.
Co-investorsAisling CapitalARCH Venture PartnersProspect Venture PartnersSchooner CapitalALTITUDE LIFE SCIENCE VENTURESFoley Ventures
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Aetna Wun Trombley(President and CEO)inAmy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)inKaren Flick(General Counsel)in
Co-investorsREDMILEVersant VenturesBAM ElevateFranklin TempletonHBM Healthcare InvestmentsJanus Henderson Investors+4 more
BiotechWatertown, US
Carlo Giovanni Traverso(Director)Amy W. Schulman(Executive Officer, Director)inRobert S. Langer(Director)
BoardZafi Avnur(Director)Edmund Harrigan(Director)Catherine Reynolds(Director)
Co-investorsBill & Melinda Gates FoundationGilead SciencesKendall Capital PartnersPolaris Partners
A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.
Biotech
Timur Yusufzai(Founder)inAsit Parikh(Chief Executive Officer)in
Co-investorsNextech InvestThird Rock VenturesAlexandriaCasdin CapitalCreacion VenturesGoldman Sachs+3 more
NextPoint is a precision therapeutics company developing cancer treatments targeting the B7-H7/HHLA2 axis, including a T-cell engager, an antibody-drug conjugate with proprietary linker technology, and a multi-functional checkpoint inhibitor.
BiotechHealthtechAustin, US
Gordon Freeman(Scientific Founder)XingXing Zang(Scientific Founder)inIvan Cheung(Chief Executive Officer)inLeena Gandhi(Chief Medical Officer)inTatiana Novobrantseva(Chief Scientific Officer)inAxel Hoos(Director)
Co-investorsCatalio Capital Management, LPMPM BioImpactSanofi VenturesCatalio Capital ManagementLeaps by BayerSixty Degree Capital
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.
BiotechHealthtechMedical Devices
Ilise Lombardo(Chief Executive Officer)inVolker Knappertz(Executive Vice President of Research & Development)inMichael Samar(Chief Financial Officer)inRob Lasser(Chief Medical Officer)in
Co-investorsBioMedPartnersJeito CapitalRoche Venture FundSofinnova PartnersEQTEQT Life Sciences+2 more
PayJoy provides financial services and credit access to unbanked and underbanked populations in emerging markets across Africa, Asia, and Latin America.
B2B MarketplacesFintechImpact & Social GoodRetail TechSan Francisco, US
Mark Heynen(Co-Founder & Chief Business Officer)inDoug Ricket(Co-Founder & CEO)inGib Lopez(Co-Founder & COO)inTom Ricket(Co-Founder)inNick Zakrasek(President, Product Development)inAmy Pardee(General Counsel)in
Co-investorsCeniarthCiti VenturesCompoundCore Venture CapitalDnx VenturesEchoVC Partners+17 more
Restoring vision through optogenetics.
BiotechSan Francisco, US
Paul Bresge(Executive Officer, Director)Sean Ainsworth(Executive Officer, Director)
BoardTiba Aynechi(Director)inDmitry Kuzmin(Director)Raymond Camahort(Director)Hannah Chang(Director)
Co-investorsMRL Ventures Fund4BIO Capital4Bio VenturesDeerfield Management CompanyFranklin TempletonJanus Henderson Investors+2 more
Sironax is a biopharmaceutical company focused on the discovery and development of therapies for neurodegenerative, inflammatory and immunological, metabolic, and rare diseases.
BiotechHealthtechLongevityWaltham, US
Dr. Xiaodong Wang(Founder)Dr. Zhiyuan Zhang(Founder)
Co-investorsARCH Venture PartnersF-Prime CapitalYuanBio Venture CapitalCBC GroupEight Roads VenturesFuture Innovation+5 more
Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases.
BiotechDigital HealthHealthtech
Vishal Patelin
Co-investorsAtlas VentureBorealis VenturesBorealis VenturesMagnetic VenturesOrbiMedAscenta Capital+3 more
Exits · 3
IPOs and acquisitions across the tracked portfolioAbsciNASDAQ: ABSIAgenusNASDAQ: AGENCyclerion TherapeuticsNASDAQ: CYCN
Portfolio news
latest coverage across their companiesCyclerion Therapeutics · thestockobserver.com · Sep 3, 2026
Agenus · simplywall.st · Aug 15, 2026
Bullhound Capital · alleywatch.com · Aug 13, 2026
Triveni · fiercebiotech.com · Aug 12, 2026
Flare · coindesk.com · Jul 30, 2026
PayJoy · Forbes · Jul 24, 2026
Frequently asked questions
- What stage does Invus invest at?
- Invus invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Invus focus on?
- Invus focuses on AI & Machine Learning, Biotech, Consumer, Crypto & Web3, Fintech, FoodTech, Healthtech, Marketplaces, SaaS, Travel & Hospitality.
- Where is Invus located?
- Invus is headquartered in New York, US.
- Who does Invus co-invest with?
- Invus most often shares deals with Citi Ventures, Compound, EchoVC Partners, among 22 tracked co-investors.
Similar investors
OMERS Ventures is a venture capital firm that invests in founders globally, with investment teams based in New York, Palo Alto, and Toronto.
AppWorks is a Taiwan-based venture capital firm and accelerator founded by former founders, backing tech startups across Greater Southeast Asia since 2009.
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
Norwest Venture Partners is an investment firm whose growth equity team backs private, profitable, fast-growing companies, providing capital and hands-on support through its 'invited guest' approach.
Notable Capital is a venture capital firm that has partnered with founders for over two decades, backing companies from the earliest stages through to exit.